Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,597
Total Claims
$1.5M
Drug Cost
638
Beneficiaries
$2,420
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+72%
Cost per patient vs peers
$2,420 vs $1,411 avg
+60%
Brand preference vs peers
17.0% vs 10.6% avg
Brand vs Generic
Brand: 3,138 claims · $1.1M
Generic: 15,358 claims · $409K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 533 | $207K |
| Etanercept | 12 | $90K |
| Dulaglutide | 98 | $80K |
| Rivaroxaban | 158 | $60K |
| Fluticasone/Umeclidin/Vilanter | 77 | $39K |
| Rifaximin | 16 | $37K |
| Vibegron | 94 | $36K |
| Semaglutide | 29 | $29K |
| Empagliflozin | 62 | $26K |
| Brexpiprazole | 27 | $22K |
| Vortioxetine Hydrobromide | 63 | $22K |
| Linaclotide | 40 | $22K |
| Sitagliptin Phosphate | 58 | $20K |
| Dapagliflozin Propanediol | 37 | $18K |
| Atorvastatin Calcium | 824 | $18K |
Prescribing Profile
Patient Profile
80
Avg Age
66%
Female
2.21
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data